Radius Health (RDUS)
Leerink Healthcare Conference

February 15, 2018

We are Radius®

Safe Harbor

Any statements made in this presentation relating to future financial or business performance, conditions, plans, prospects, trends or strategies and other financial or business matters, including regarding the commercialization of TYMLOS™ (abaloparatide) injection in the U.S., the development and potential commercialization of our product candidates, clinical trial results, regulatory actions and communications, potential collaborations, future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when used in this presentation, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predicts”, “targets” and similar expressions and their variants, as they relate to Radius Health, Inc. (“Radius”) or its management, may identify forward-looking statements. Radius cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Radius to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization of TYMLOS in the U.S., or potential commercialization of any of Radius’ proposed product candidates if approved, (such as marketing, regulatory, patent, product liability, supply, competition and other risks); dependence on the efforts of third parties; dependence on and challenges to our intellectual property rights; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Radius’ business, financial conditions and results of operations and could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation are contained under the caption “risk factors” in Radius’ Quarterly Report on Form 10-Q for the period ended June 30, 2017, along with Radius’ other reports filed with the Securities and Exchange Commission. The forward-looking statements in this presentation represent Radius’ estimate as of the date of this presentation only, and Radius specifically disclaIQVIA any duty or obligation to update forward-looking statements.

Leading, fully integrated biopharmaceutical company committed to bone health and oncology through innovative therapies

	Bone Health	Oncology
Commercial	• TYMLOS Anabolic #1 Market Leadership • Go Global, Partner OUS • Expand and differentiate label to own OP • Disrupt the market with TYMLOS patch opportunity	• Foothold in Breast Cancer through potential Elacestrant backbone hormonal therapy • Partner Elacestrant development in earlier lines of therapy and OUS • Fuel Breast Cancer Pipeline with SARM RAD140

Corporate

- Lean structure to support front line customer facing OP and BC capabilities
- Be an Attractive Partner for innovation
- Become a ‘Best Place to Work” in the US

Radius Pipeline of Investigational Drugs

	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	REGULATORY REVIEW	MARKET
Abaloparatide-SC Osteoporosis Anabolic *SC injection*	*Post menopausal women (U.S.)*					TYMLOS™ (abaloparatide) injection
	Post menopausal women (EU)					
	Male					
Abaloparatide Patch Osteoporosis Anabolic *Transdermal Patch*						
Elacestrant Breast Cancer *Oral SERD*						
RAD140 Breast Cancer *Oral SARM*						

Radius

TYMLOS Market Share Continues to Improve

TYMLOS Anabolic Market Share
(NBRx, New PMOT & PMOT)



Source: IQVIA NPA Weekly and New to Brand Weekly, week ending 2/2/2018

Elacestrant's impressive single agent activity warrants advancement to a potentially pivotal clinical trial

SABCS 2017

- Update included mature data from Parts A, B and C (30 Oct 2017 data cutoff)
  - Objective Response Rate (ORR^) = **27.3%**
  - Clinical Benefit Rate (CBR) = **47.4%**
  - Median Progression Free Survival (mPFS) = **5.4 months**
- Responses documented in patients with prior fulvestrant therapy, prior CDK4/6i therapy and in patients with ESR1 mutations
- 10 out of 40 patients continue on treatment as of 30 October 2017; only 5 patients discontinued since 28 April 2017 cutoff
- Well tolerated; most common AEs were low-grade nausea, dyspepsia, and vomiting
- Data supports advancement of elacestrant to potentially pivotal Phase 2 study

Clinical study protocol under review by FDA and EMA. Expect to provide an update on March 1, 2018.

ASCO 28 April 2017 data cut off: ORR = 23%, CBR = 41.7%, mPFS = 4.5mths
^ 22 patients had RECIST measurable disease